1 Vote
Benefits of Alimta in Patients with Malignant Pleural Mesothelioma « Pleural Mesothelioma
http://www.keysbatonrouge.com —
Data from two large studies show that open patients had survival rates at one year than 50% when treated with ALIMTA (R) (pemetrexed for injection) or with plans to base of ALIMTA for the treatment of malignant pleural mesothelioma (MPM) in both first and second line. The study results demonstrate significant benefits in efficiency and safety for ALIMTA Eli Lilly and Company, the only known agent demonstrating a survival benefit in this disease often difficult to treat and is mainly linked to exposure to asbestos. The data were presented today at the Twelfth World Conference on Lung Cancer.
Comments